Progressive Multiple Sclerosis Clinical Trial
Official title:
Exploratory Trial of Forza™️, a Novel Nutraceutical From Actinidia Deliciosa Plants Bioengineered to Bio-encapsulate the Osmotin Plant Protein as Adjuvant for the Treatment of Progressive Multiple Sclerosis
The aim of this study is to explore the anti-inflammatory and neuroprotective effects of a novel nutraceutical product (commercial name Forza™️), consisting of the plant osmotin protein, in patients with progressive multiple sclerosis (PMS). The potential effect on brain metabolism and microstructure will be evaluated by magnetic resonance imaging (MRI) performed six months before starting treatment, at baseline, and after one and six months of treatment. At the same timepoints, electrophysiology, neurofilaments (NfL) quantification, optical coherence tomography (OCT) and clinical assessments will be performed.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02282826 -
A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
|
Phase 1 | |
| Completed |
NCT02804594 -
A Study of Oxidative Pathways in MS Fatigue
|
Phase 2 | |
| Completed |
NCT04120675 -
Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis
|
N/A | |
| Completed |
NCT01719159 -
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis
|
Phase 2 | |
| Enrolling by invitation |
NCT03552211 -
Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis
|
||
| Recruiting |
NCT05740722 -
Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT03980145 -
G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis
|
N/A | |
| Completed |
NCT03269071 -
Neural Stem Cell Transplantation in Multiple Sclerosis Patients
|
Phase 1 | |
| Not yet recruiting |
NCT05811013 -
Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis
|
N/A | |
| Not yet recruiting |
NCT04289909 -
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
|
N/A | |
| Recruiting |
NCT05685784 -
Multiple Sclerosis Prediction and Monitoring of Progression Study
|
N/A | |
| Completed |
NCT03493841 -
Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis
|
Phase 1 | |
| Completed |
NCT03302806 -
Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis
|
||
| Recruiting |
NCT05441488 -
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
|
Phase 3 | |
| Recruiting |
NCT04695080 -
ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06451159 -
A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
|
Phase 1 | |
| Completed |
NCT03423121 -
A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
| Terminated |
NCT02580669 -
Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis
|
N/A | |
| Enrolling by invitation |
NCT05706220 -
Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
|
||
| Recruiting |
NCT01815632 -
Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)
|
Phase 2 |